{"id":"flt3","name":"FLT3","symbol":"FLT3","route":"/targets/flt3/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122025","uniprot":"https://www.uniprot.org/uniprotkb/P36888/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P36888","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1974","open-targets":"https://platform.opentargets.org/target/ENSG00000122025","civic":"https://civicdb.org/genes/2322/summary","oncokb":"https://www.oncokb.org/gene/FLT3","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FLT3","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FLT3","depmap":"https://depmap.org/portal/gene/FLT3?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000122025-FLT3","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2322","omim":"https://www.omim.org/entry/136351"}],"products":[{"id":"fedratinib","name":"Fedratinib","status":"approved","modality":"Small-molecule JAK2/FLT3 inhibitor","route":"/drugs/fedratinib/"},{"id":"gilteritinib","name":"Gilteritinib","status":"approved","modality":"Small-molecule kinase inhibitor (FLT3, type I)","route":"/drugs/gilteritinib/"},{"id":"men1703","name":"MEN1703","status":"phase-2","modality":"small molecule (kinase inhibitor)","route":"/drugs/men1703/"},{"id":"midostaurin","name":"Midostaurin","status":"approved","modality":"Small-molecule multikinase inhibitor (FLT3)","route":"/drugs/midostaurin/"},{"id":"pacritinib","name":"Pacritinib","status":"approved","modality":"Small-molecule JAK2/IRAK1/ACVR1 inhibitor","route":"/drugs/pacritinib/"},{"id":"quizartinib","name":"Quizartinib","status":"approved","modality":"Small-molecule kinase inhibitor (FLT3-ITD, type II)","route":"/drugs/quizartinib/"}],"trials":[{"id":"nct03182244","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","nct":"NCT03182244","phase":"3","status":"completed"},{"id":"morpho","name":"MORPHO","nct":"NCT02997202","phase":"3","status":"mixed"},{"id":"quantum-first","name":"QuANTUM-First","nct":"NCT02668653","phase":"3","status":"positive"},{"id":"admiral","name":"ADMIRAL","nct":"NCT02421939","phase":"3","status":"positive"},{"id":"ratify","name":"RATIFY (CALGB 10603)","nct":"NCT00651261","phase":"3","status":"positive"},{"id":"nct04293562","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","nct":"NCT04293562","phase":"3","status":"recruiting"},{"id":"beat-aml-master-trial","name":"Beat AML Master Trial","nct":"NCT03013998","phase":"platform","status":"recruiting"},{"id":"nct03591510","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","nct":"NCT03591510","phase":"2","status":"active"},{"id":"nct06824168","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","nct":"NCT06824168","phase":"2","status":"recruiting"},{"id":"nct06534437","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","nct":"NCT06534437","phase":"2","status":"recruiting"},{"id":"nct07033598","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","nct":"NCT07033598","phase":"2","status":"recruiting"},{"id":"nct04988555","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","nct":"NCT04988555","phase":"1/2","status":"recruiting"},{"id":"nct05520567","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","nct":"NCT05520567","phase":"1/2","status":"active"},{"id":"nct04817007","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","nct":"NCT04817007","phase":"1/2","status":"active"},{"id":"nct03793478","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","nct":"NCT03793478","phase":"1/2","status":"active"}],"pathways":["aml-signalling","menin-kmt2a"],"companies":["aptose","arog-pharmaceuticals","astellas","bms","cullinan-therapeutics","daiichi-sankyo","novartis","ryvu-therapeutics","sobi"],"keyPapers":["paper-quantum-first-quizartinib-lancet-2023","paper-admiral-gilteritinib-flt3-nejm-2019"],"hotspots":[{"label":"Internal tandem duplication (ITD)","position":572,"kind":"activating","frequency":"About 25% of AML","drugs":["midostaurin","gilteritinib","quizartinib"]},{"label":"D835Y/V/H (TKD)","position":835,"kind":"activating","frequency":"About 7% of AML","drugs":["gilteritinib","midostaurin"]},{"label":"F691L (gatekeeper)","position":691,"kind":"resistance","drugs":[]}],"openQuestions":[],"assays":[{"id":"flt3-leukostrat","name":"LeukoStrat CDx FLT3 Mutation Assay","cutoff":"ITD signal ratio at least 0.05 or TKD mutation detected (midostaurin, gilteritinib); ITD only for quizartinib"}],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}